T. Liu

Development of Personalized Combination Cancer Immunotherapy Based on the Patients’ Immune Status

T. Sakurai, Y. Kawakami, T. Kinoshita, 2015 .

Cancer Induced Immunosuppression and Its Modulation by Signal Inhibitors

T. Sakurai, Y. Kawakami, T. Kinoshita, 2015 .

A global metagenomic map of urban microbiomes and antimicrobial resistance

Stephanie L. Hyland, Nora C. Toussaint, Paweł P. Łabaj, 2021, Cell.

A Phase 1b, Dose-Finding Study Of Ruxolitinib Plus Panobinostat In Patients With Primary Myelofibrosis (PMF), Post–Polycythemia Vera MF (PPV-MF), Or Post–Essential Thrombocythemia MF (PET-MF): Identification Of The Recommended Phase 2 Dose

S. Acharyya, A. Vannucchi, F. Passamonti, 2013 .

Efficacy, Safety, and Confirmation of the Recommended Phase 2 Starting Dose of the Combination of Ruxolitinib (RUX) and Panobinostat (PAN) in Patients (Pts) with Myelofibrosis (MF)

S. Acharyya, A. Vannucchi, F. Passamonti, 2015 .